• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
Ann Rheum Dis. Feb 1994; 53(2): 112–116.
PMCID: PMC1005262

A randomised controlled trial of the effect of hormone replacement therapy on disease activity in postmenopausal rheumatoid arthritis.

Abstract

OBJECTIVE--To assess the effects of hormone replacement therapy (HRT) on disease activity in postmenopausal rheumatoid arthritis (RA). METHODS--Two hundred postmenopausal outpatients (aged 45-65 years) were admitted into a single blind randomised placebo controlled trial of transdermal oestradiol (50 micrograms daily) over six months. Patients continued with routine antirheumatic medications. Compliance with HRT was monitored using serum oestradiol (E2) levels. Disease activity was monitored at entry, three and six months using erythrocyte sedimentation rate (ESR), articular index (AI), visual analogue pain scale (VPS) and early morning stiffness (EMS). RESULTS--Ninety one and 77 patients completed six months treatment with placebo and HRT respectively. There were no significant differences in baseline characteristics between the groups and no overall effects of treatment. However, 35 patients (41.6%), who completed HRT, failed to achieve serum E2 levels > 100 pmol/l at either three or six months and were considered 'poor-compliers'. In the remaining HRT 'compliers' (58.4%) there were significant improvements after six months in articular index (28.9%; p < 0.01) and pain score (21.7%; p < 0.05) compared with placebo, as well as reductions in ESR (8.9%; NS) and morning stiffness (25.2%; NS). Comparisons between HRT 'compliers' and 'poor-compliers' confirmed significant improvements in articular index (p < 0.001), pain score (p < 0.05) and morning stiffness (p < 0.001) in the 'compliers'. CONCLUSIONS--This study did not show an overall effect of HRT on disease activity when used as an adjunct therapy in postmenopausal patients. A subgroup of patients, who had greater increments in serum E2 whilst taking HRT, demonstrated improvements in some parameters of disease activity, suggesting a potential beneficial effect with good compliance and higher dose HRT. Most importantly, in the treatment of RA associated bone loss, HRT can be prescribed without fear of a disease flare up.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (937K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Oka M, Vainio U. Effect of pregnancy on the prognosis and serology of rheumatoid arthritis. Acta Rheumatol Scand. 1966;12(1):47–52. [PubMed]
  • Ostensen M, Aune B, Husby G. Effect of pregnancy and hormonal changes on the activity of rheumatoid arthritis. Scand J Rheumatol. 1983;12(2):69–72. [PubMed]
  • Pope RM, Yoshinoya S, Rutstein J, Persellin RH. Effect of pregnancy on immune complexes and rheumatoid factors in patients with rheumatoid arthritis. Am J Med. 1983 Jun;74(6):973–979. [PubMed]
  • Spector TD, Hochberg MC. The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol. 1990;43(11):1221–1230. [PubMed]
  • DUTHIE JJ, BROWN PE, TRUELOVE LH, BARAGAR FD, LAWRIE AJ. COURSE AND PROGNOSIS IN RHEUMATOID ARTHRITIS. A FURTHER REPORT. Ann Rheum Dis. 1964 May;23:193–204. [PMC free article] [PubMed]
  • Rasker JJ, Cosh JA. The natural history of rheumatoid arthritis: a fifteen year follow-up study. The prognostic significance of features noted in the first year. Clin Rheumatol. 1984 Mar;3(1):11–20. [PubMed]
  • Sherrer YS, Bloch DA, Mitchell DM, Young DY, Fries JF. The development of disability in rheumatoid arthritis. Arthritis Rheum. 1986 Apr;29(4):494–500. [PubMed]
  • Holmdahl R, Jansson L, Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum. 1986 Dec;29(12):1501–1509. [PubMed]
  • Holmdahl R, Jansson L, Meyerson B, Klareskog L. Oestrogen induced suppression of collagen arthritis: I. Long term oestradiol treatment of DBA/1 mice reduces severity and incidence of arthritis and decreases the anti type II collagen immune response. Clin Exp Immunol. 1987 Nov;70(2):372–378. [PMC free article] [PubMed]
  • Paavonen T, Andersson LC, Adlercreutz H. Sex hormone regulation of in vitro immune response. Estradiol enhances human B cell maturation via inhibition of suppressor T cells in pokeweed mitogen-stimulated cultures. J Exp Med. 1981 Dec 1;154(6):1935–1945. [PMC free article] [PubMed]
  • Pacifici R, Rifas L, McCracken R, Vered I, McMurtry C, Avioli LV, Peck WA. Ovarian steroid treatment blocks a postmenopausal increase in blood monocyte interleukin 1 release. Proc Natl Acad Sci U S A. 1989 Apr;86(7):2398–2402. [PMC free article] [PubMed]
  • GILBERT M, ROTSTEIN J, CUNNINGHAM C, ESTRIN I, DAVIDSON A, PINCUS G. NORETHYNODREL WITH MESTRANOL IN TREATMENT OF RHEUMATOID ARTHRITIS. JAMA. 1964 Oct 19;190:235–235. [PubMed]
  • Bijlsma JW, Huber-Bruning O, Thijssen JH. Effect of oestrogen treatment on clinical and laboratory manifestations of rheumatoid arthritis. Ann Rheum Dis. 1987 Oct;46(10):777–779. [PMC free article] [PubMed]
  • Selby PL, Peacock M. Dose dependent response of symptoms, pituitary, and bone to transdermal oestrogen in postmenopausal women. Br Med J (Clin Res Ed) 1986 Nov 22;293(6558):1337–1339. [PMC free article] [PubMed]
  • Powers MS, Schenkel L, Darley PE, Good WR, Balestra JC, Place VA. Pharmacokinetics and pharmacodynamics of transdermal dosage forms of 17 beta-estradiol: comparison with conventional oral estrogens used for hormone replacement. Am J Obstet Gynecol. 1985 Aug 15;152(8):1099–1106. [PubMed]
  • Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med. 1991 Jan;20(1):47–63. [PubMed]
  • Paganini-Hill A, Ross RK, Gerkins VR, Henderson BE, Arthur M, Mack TM. Menopausal estrogen therapy and hip fractures. Ann Intern Med. 1981 Jul;95(1):28–31. [PubMed]
  • Hall GM, Spector TD, Studd JW. Carpal tunnel syndrome and hormone replacement therapy. BMJ. 1992 Feb 8;304(6823):382–382. [PMC free article] [PubMed]
  • Ryan PJ, Harrison R, Blake GM, Fogelman I. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol. 1992 Apr;99(4):325–328. [PubMed]
  • Holmdahl R, Carlsten H, Jansson L, Larsson P. Oestrogen is a potent immunomodulator of murine experimental rheumatoid disease. Br J Rheumatol. 1989;28 (Suppl 1):54–71. [PubMed]
  • Mattsson R, Mattsson A, Holmdahl R, Whyte A, Rook GA. Maintained pregnancy levels of oestrogen afford complete protection from post-partum exacerbation of collagen-induced arthritis. Clin Exp Immunol. 1991 Jul;85(1):41–47. [PMC free article] [PubMed]
  • da Silva JA. Heat shock proteins: the missing link between hormonal and reproductive factors and rheumatoid arthritis? Ann Rheum Dis. 1991 Oct;50(10):735–739. [PMC free article] [PubMed]
  • Paavonen T, Andersson LC. The oestrogen antagonists, tamoxifen and FC-1157a, display oestrogen like effects on human lymphocyte functions in vitro. Clin Exp Immunol. 1985 Aug;61(2):467–474. [PMC free article] [PubMed]
  • Stimson WH. Oestrogen and human T lymphocytes: presence of specific receptors in the T-suppressor/cytotoxic subset. Scand J Immunol. 1988 Sep;28(3):345–350. [PubMed]
  • Seaman WE, Blackman MA, Gindhart TD, Roubinian JR, Loeb JM, Talal N. beta-Estradiol reduces natural killer cells in mice. J Immunol. 1978 Dec;121(6):2193–2198. [PubMed]
  • Screpanti I, Santoni A, Gulino A, Herberman RB, Frati L. Estrogen and antiestrogen modulation of the levels of mouse natural killer activity and large granular lymphocytes. Cell Immunol. 1987 May;106(2):191–202. [PubMed]
  • Luster MI, Hayes HT, Korach K, Tucker AN, Dean JH, Greenlee WF, Boorman GA. Estrogen immunosuppression is regulated through estrogenic responses in the thymus. J Immunol. 1984 Jul;133(1):110–116. [PubMed]
  • Weusten JJ, Blankenstein MA, Gmelig-Meyling FH, Schuurman HJ, Kater L, Thijssen JH. Presence of oestrogen receptors in human blood mononuclear cells and thymocytes. Acta Endocrinol (Copenh) 1986 Jul;112(3):409–414. [PubMed]
  • Stimson WH, Hunter IC. Oestrogen-induced immunoregulation mediated through the thymus. J Clin Lab Immunol. 1980 Jul;4(1):27–33. [PubMed]
  • Tazuke S, Khaw KT, Barrett-Connor E. Exogenous estrogen and endogenous sex hormones. Medicine (Baltimore) 1992 Jan;71(1):44–51. [PubMed]
  • Lobo RA, Goebelsmann U, Brenner PF, Mishell DR., Jr The effects of estrogen on adrenal androgens in oophorectomized women. Am J Obstet Gynecol. 1982 Feb 15;142(4):471–478. [PubMed]
  • Spector TD, Hall GM, McCloskey EV, Kanis JA. Risk of vertebral fracture in women with rheumatoid arthritis. BMJ. 1993 Feb 27;306(6877):558–558. [PMC free article] [PubMed]
  • van den Brink HR, Lems WF, van Everdingen AA, Bijlsma JW. Adjuvant oestrogen treatment increases bone mineral density in postmenopausal women with rheumatoid arthritis. Ann Rheum Dis. 1993 Apr;52(4):302–305. [PMC free article] [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • Compound
    Compound
    PubChem Compound links
  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...